Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for >= 156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

摘要

Background: Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective: Assess long-term safety of oral apremilast in psoriasis patients.